Medi-Physics full-scale launch of cardiac imaging agent Myoview planned for April.
This article was originally published in The Gray Sheet
Executive SummaryMEDI-PHYSICS' MYOVIEW SCINTIGRAPHIC CARDIAC IMAGING AGENT Full-scall launch is slated for April, the company says. Approved by FDA Feb. 9, Myoview (technetium Tc99m tetrofosmin) is indicated for "scintigraphic imaging of the myocardium following separate administrations under exercise and resting conditions." The product is "useful in the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium," labeling states.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.